

ANONYMOUS

Witness Name: **GRO-B**

Statement No: WITN2147001

Exhibits: WITN2147002 - 015

Dated: 10th November 2020

INFECTED BLOOD INQUIRY

EXHIBIT WITN2147004

ANONYMOUS

000074

GRO-B

GRO-B

GRO-B

Telephone
41-201 0000

Direct Line

GRO-B

GRO-B
Glasgow GRO-B

GRO-B

DEPARTMENT OF HAEMATOLOGY

(Dictated: 10/12/94)
12th December 1994

Dr GRO-B
The GRO-B

GRO-B

Dear Dr GRO-B

Re: GRO-B DATE OF BIRTH: GRO-B H.N: GRO-B
GRO-B GRO-B GRO-B GRO-B

I saw GRO-B for her annual review on 9th December. She will soon be 16 years old, having been diagnosed at the age of 2 years and off treatment for the past 11 years. Her general health is excellent and she has no more problems with infections than her peers. She plays sport, both badminton and cycling. She copes averagely at school and will take 8 standard grades. Her periods are regular with a 42 days cycle and 7 day duration. Examination was unremarkable and in particular, her liver was not palpable and she had no stigmata of liver disease. Her haemoglobin was 13.8 g/dl, white cell count $5.0 \times 10^9/L$, neutrophils $3.2 \times 10^9/L$ and platelet count $182 \times 10^9/L$.

GRO-B is extremely well from the viewpoint of her leukaemia. Despite impressive improvements in the survival rate for childhood leukaemia, we are becoming increasingly aware of treatment-related late effects. Because of reports of Hepatitis C positivity in children treatment for leukaemia, GRO-B was recently screened and unfortunately has both antibody to Hepatitis C and Hepatitis C RNA detected by PCR indicating the presence of virus. Her liver function tests are mildly elevated with an AST of 57 U/L and ALT 101 U/L. Her ferritin is normal at 30 $\mu g/L$. GRO-B has been extremely unfortunate in acquiring Hepatitis C infection as at the time she was treated, chemotherapy was relatively mild compared to what is now used, and as a result children then received fewer blood products. Unfortunately it only requires one contaminated unit. I informed both Mrs GRO-B and GRO-B of her Hepatitis C status. Although they handled the information sensibly, they were both clearly worried. It is a very difficult scenario as we don't really know what the long-term outlook for patients with Hepatitis C infection post-transfusion will be and neither do we know the benefits of Interferon. GRO-B is one of a number of children who have been affected and it is likely that we will arrange liver biopsies early next year to determine the degree of damage. Mrs GRO-B is aware that GRO-B will be recalled before her next clinic visit. If you would like to telephone me about GRO-B I would be very happy to speak to you as I am sure Mrs GRO-B will contact you.

Yours sincerely

GRO-C

B E S GIBSON
CONSULTANT HAEMATOLOGIST

WITN2147004_0002